scholarly journals An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is)

2021 ◽  
Vol Volume 14 ◽  
pp. 2955-2972
Author(s):  
Song Wen ◽  
Thiquynhnga Nguyen ◽  
Min Gong ◽  
Xinlu Yuan ◽  
Chaoxun Wang ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Receptor Agonists ◽  
Similarities And Differences ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain–Gut Axis

2015 ◽  
Vol 35 (5) ◽  
pp. 1092-1100 ◽  
Author(s):  
Sarah Farr ◽  
Christopher Baker ◽  
Mark Naples ◽  
Jennifer Taher ◽  
Jahangir Iqbal ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Lipoprotein Metabolism ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing

Diabetes ◽  
2008 ◽  
Vol 57 (10) ◽  
pp. 2603-2612 ◽  
Author(s):  
C. Knauf ◽  
P. D. Cani ◽  
D.-H. Kim ◽  
M. A. Iglesias ◽  
C. Chabo ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Glucose Sensing ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4

Endocrinology ◽  
2011 ◽  
Vol 152 (8) ◽  
pp. 3103-3112 ◽  
Author(s):  
Scott E. Kanoski ◽  
Samantha M. Fortin ◽  
Myrtha Arnold ◽  
Harvey J. Grill ◽  
Matthew R. Hayes
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Body Weight ◽  
Food Intake ◽  
Vagal Afferents ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Long Acting ◽  
Higher Doses ◽  
Cns Delivery

The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, exendin-4 and liraglutide, suppress food intake and body weight. The mediating site(s) of action for the anorectic effects produced by peripheral administration of these GLP-1R agonists are not known. Experiments addressed whether food intake suppression after ip delivery of exendin-4 and liraglutide is mediated exclusively by peripheral GLP-1R or also involves direct central nervous system (CNS) GLP-1R activation. Results showed that CNS delivery [third intracerebroventricular (3rd ICV)] of the GLP-1R antagonist exendin-(9–39) (100 μg), attenuated the intake suppression by ip liraglutide (10 μg) and exendin-4 (3 μg), particularly at 6 h and 24 h. Control experiments show that these findings appear to be based neither on the GLP-1R antagonist acting as a nonspecific competing orexigenic signal nor on blockade of peripheral GLP-1R via efflux of exendin-(9–39) to the periphery. To assess the contribution of GLP-1R expressed on subdiaphragmatic vagal afferents to the anorectic effects of liraglutide and exendin-4, food intake was compared in rats with complete subdiaphragmatic vagal deafferentation and surgical controls after ip delivery of the agonists. Both liraglutide and exendin-4 suppressed food intake at 3 h, 6 h, and 24 h for controls; for subdiaphragmatic vagal deafferentation rats higher doses of the GLP-1R agonists were needed for significant food intake suppression, which was observed at 6 h and 24 h after liraglutide and at 24 h after exendin-4. Conclusion: Food intake suppression after peripheral administration of exendin-4 and liraglutide is mediated by activation of GLP-1R expressed on vagal afferents as well as direct CNS GLP-1R activation.

Sign in / Sign up

Export Citation Format

Share Document